Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Charlottesville focused on cardiometabolic health, recently completed a $132 million Series B financing round.
The funding was led by Boston’s RA Capital Management with participation from Boston’s Bain Capital Life Sciences, Switzerland’s BB Biotech AG and existing investors Longitude Capital of Menlo Park, California as well as Medicxi and RxCapital, both based in the U.K.
The new investment brings Rivus’ lifetime funding to $167 million, according to Crunchbase.
Rivus said the financing will support further clinical advancement of lead drug candidate HU6, what it bills as a first-in-class controlled metabolic accelerator, or CMA, designed to treat cardiometabolic diseases.
“While there have been several recent clinical successes in the treatment of obesity, CMAs stand alone in their ability to demonstrate significant fat reduction while sparing muscle mass, a very desirable profile especially…
Read the full story from the Washington Business Journal.
